Niesvizky, Ruben; Badros, Ashraf Z.; Costa, Luciano J. et al.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaLEUKEMIA & LYMPHOMA. Bd. 56. H. 12. 2015 S. 3320-3328
Eberhardt, Wilfried Ernst Erich; Poettgen, Christoph; Gauler, Thomas Christoph et al.
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)JOURNAL OF CLINICAL ONCOLOGY. Bd. 33. H. 35. 2015 S. 4194-+
Mai, E. K.; Bertsch, U.; Duerig, J. et al.
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaLEUKEMIA. Bd. 29. H. 8. 2015 S. 1721-1729
Versluis, Jurjen; Hazenberg, Carin L. E.; Passweg, Jakob R. et al.
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysisLANCET HAEMATOLOGY. Bd. 2. H. 10. 2015 S. E427-E436
Tiede, Andreas; Klamroth, Robert; Scharf, Ruediger E. et al.
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 studyBLOOD. Bd. 125. H. 7. 2015 S. 1091-1097
Ritz, Sandra; Schoettler, Susanne; Kotman, Niklas et al.
Protein Corona of Nanoparticles: Distinct Proteins Regulate the Cellular UptakeBIOMACROMOLECULES. Bd. 16. H. 4. 2015 S. 1311-1321
Ulges, Alexander; Klein, Matthias; Reuter, Sebastian et al.
Protein kinase CK2 enables regulatory T cells to suppress excessive T(H)2 responses in vivoNATURE IMMUNOLOGY. Bd. 16. H. 3. 2015 S. 267-U227
Worth, H.; Buhl, R.; Criee, C-P et al.
REAL LIFE DISTRIBUTION OF COPD SEVERITY IN THE GERMAN DACCORD REGISTRY: LUNG FUNCTION IS THE MAIN DRIVER OF CLASSIFICATION IN GOLD GROUP C AND DTHORAX. Bd. 70. 2015 S. A135-A135
Castro, Mario; Zangrilli, James; Wechsler, Michael E. et al.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsLANCET RESPIRATORY MEDICINE. Bd. 3. H. 5. 2015 S. 355-366
Kirschey, Sebastian; Flohr, Thomas; Wolf, Hans H. et al.
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre studyBRITISH JOURNAL OF HAEMATOLOGY. Bd. 168. H. 6. 2015 S. 824-834